Gilead Sciences, Inc.

NASDAQ:GILD   3:59:58 PM EDT
67.24
+0.25 (+0.37%)
Products

U.S. FDA Approves Kite’S Tecartus As The First And Only Car T For Adults With Relapsed Or Refractory B-Cell Acute Lymphoblastic Leukemia

Published: 10/01/2021 21:56 GMT
Gilead Sciences, Inc. (GILD) - U.S. FDA Approves Kite’s Tecartus® As the First and Only Car T for Adults With Relapsed Or Refractory B-cell Acute Lymphoblastic Leukemia.